| 摘要: |
| 目的评价干扰素辅助治疗对局限性肾透明细胞癌患者术后免疫指标的影响及其临床意义。方法对35例局限性肾透明细胞癌患者术后应用干扰素α-2b进行免疫辅助治疗,6 MIU/次,每周3次,共持续3个月。免疫治疗前以及治疗开始后第1、2、4、8、16周抽取外周血，检测细胞免疫相关指标CD4+、CD8+、CD4+/CD8+、CD16+56+、CD19+和体液免疫相关指标IL-2、IL-6、IL-10、IL-8、TNF-α,比较各免疫指标手术前后的变化。结果免疫治疗3个月疗程结束后,患者细胞免疫指标CD4+、CD8+、CD4+/CD8+与治疗前比较差异无统计学意义;CD16+56+在治疗开始后前两周升高，第2周时与治疗前比较差异有统计学意义(P<0.05),但在第16周时较治疗前下降(P<0.01)；CD19+在治疗开始后第1、2、4周较治疗前降低(P均<0.01),但在第16周时较治疗前升高(P<0.01)。体液免疫各项指标中,IL-8水平在治疗开始后第4周时较治疗前降低 (P<0.05),TNF-α在治疗开始后第8周时较治疗前升高(P<0.01)。治疗结束后,即第16周时,所有体液免疫指标与治疗前比较差异均无统计学意义。结论局限性肾透明细胞癌术后应用干扰素免疫辅助治疗(6 MIU/次,每周3次,共持续3个月) 对于提高患者部分免疫指标水平效果不明显,此免疫治疗方案对患者远期生存期的影响需要进一步随访观察。 |
| 关键词: 肾肿瘤 免疫疗法 干扰素α-2b 免疫功能 |
| DOI：10.3724/SP.J.1008.2012.001028 |
| 投稿时间：2012-03-15修订日期：2012-05-07 |
| 基金项目:上海市市级医院新兴前沿科技联合攻关项目(SHDC12010115), 上海市重点学科项目. |
|
| Immune function analysis after interferon treatment in post-surgery patients with localized clear cell renal cell carcinoma |
| CHEN Wei1△,ZHANG Jin-ping2△,WANG Lin-hui1,YANG Qing1,LIU Bing1,WU Zhen-jie1,XU Zun-li1,SUN Ying-hao1* |
(1. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China;
2. Department of Urology, No. 401 Hospital of PLA, Qingdao 266071, Shandong, China
△Co-first authors.
*Corresponding author.) |
| Abstract: |
| ObjectiveTo evaluate the influence of interferon adjuvant therapy on immune parameters in postoperative patients with localized clear cell renal cell carcinoma (LCCRCC) and explore the related clinical significance. Methods Thirty-five patients with LCCRCC were treated with interferon α-2b hypodermic injection after surgery (6 MIU/time, three times per week for three months). Immune parameters, including CD4+,CD8+,CD4+/CD8+,CD16+56+,CD19+ , IL-2, IL-6, IL-10, IL-8, and TNF-α, were determined before and at the 1st , 2nd, 4th, 8th, and 16th week after therapy. And the results were compared before and after therapy. ResultsThree months after therapy, the levels of CD4+, CD8+ and CD4+/CD8+ were not significantly different from those before therapy. The of CD16+56+ was increased significantly during the first two weeks’ of treatment (P<0.05) and was significantly declined at the end of therapy (P<0.01). Compared with that before therapy, CD19+ levels were decreased in the 1st, 2nd and 4th week after treatment (all P<0.01), and was significantly increased at the 16th week (P<0.01). The level of IL-8 was significantly decreased at the 4th week after therapy (P<0.05) and TNF-α level was increased at the 8th week after therapy (P<0.01); the levels of other humoral immune parameters were not significantly different from those before therapy. Conclusion Treatment with interferon α-2b hypodermic injection (6 MIU/time, three times/week for three months) has a limited effect on promoting the immunity of patients with LCCRCC, and its influence on the long-term survival patients also needs further study. |
| Key words: kidney neoplasms immunotherapy interferon alfa-2b immune function |
